Engelsk titel: Biological treatment of ankylosing spondylitis
Läs online
Författare:
Freisleben S
;
Schou M
Email: marsch04@heh.regionh.dk
Språk: Dan
Antal referenser: 40
Dokumenttyp:
Översikt
UI-nummer: 08061243
Sammanfattning
All of the three well-known TNF alfa inhibitors (infliximab, adalimumab and etanercept) have a rapidly occurring and long-lasting effect in ankylosing spondylitis (AS). The IL-1 antagonist, anakinra, has been investigated in 2 open label studies with partially conflicting results. Apart from infusion reactions and local reactions which rarely are of clinical importance, infections appear significantly more often in the TNF alfa inhibitor groups compared to placebo groups. Most of the infections observed have been minor, but serious infections, including tuberculosis, have been described.